CHIMERIC EQUIVALENTS OF LIGANS OF SOMATOSTATIN AND DOPERMINE RECEPTORS, PHARMACEUTICAL COMPOSITIONS BASED ON THEM AND MODALTIES OF SOMATOSTATIN AND/DOPERMINE RECEPTORS

摘要

FIELD: chemistry. ^ SUBSTANCE: invention pertains to chemeric equivalent of somatostatin, chosen from DPhe- cyclo(Cys- 3ITyr-DTrp-Lys-Val-Cys)-Thr-NH2, DPhe-cyclo(Cys-3ITyr-DTrp-Lys-Thr-Cys)-Thr-NH2, DPhe-cyclo(Cys-Tyr-DTrp-Lys-Abu-Cys)-Thr-NH2, cyclo(Cys-Tyr-DTrp-Lys-Abu-Cys)-Thr-NH2, DTyr-DTyr-cyclo(Cys-Tyr-DTrp-Lys-Abu-Cys)Thr-NH2 and DTyr-DTyr-cyclo(Cys-3ITyr-DTrp-Lys-Thr-Cys)Thr-NH2 and a fragment, joined to a dopermine receptor, chosen from Dop2 , Dop3 , Dop4 and Dop5 . Methods are proposed of obtaining agonistic effect (1) to dopermine receptors; (2) to somatostatin receptors and (3) to dopermine and/or somatostatin receptors, which include introduction of an effective quantity of a chimeric equivalent of a subject in need. A pharmaceutical composition is proposed, which has agonistic effect to dopermine and/or somatostatin receptors, including an effective quantity of a chimeric equivalent. ^ EFFECT: chimeric equivalent, with agonistic effect to a dopermine and/or somatostatin receptor. ^ 31 cl, 13 ex, 1 tbl